Pharmacy Benefit Managers Report Reveals Escalating Drug Costs and Calls for Regulation

By Rene Pretorius

February 14, 2025

The Federal Trade Commission (FTC) has released a pharmacy benefit managers report that presents crucial findings on the impact of the three major pharmacy benefit managers (PBMs): CVS Caremark, Express Scripts, and Optum Rx. These entities serve as intermediaries in the prescription drug market, and the report details how they significantly marked up the prices of specialty generic drugs. Medications for cancer, HIV, and heart disease experienced increases often reaching hundreds or even thousands of percent.

Financial Impact of PBMs on Drug Prices

Pharmacy benefit managers (PBMs) significantly affect the prices of lifesaving drugs, with their affiliated pharmacies earning over $7.3 billion in dispensing revenue, surpassing the acquisition costs for specialty generics between 2017 and 2022.

Spread Pricing Generates Profits

The Big Three PBMs earned about $1.4 billion from spread pricing on specialty generic drugs. Spread pricing involves PBMs charging clients more than what they pay pharmacies for the drugs.

PBM Practices Under Scrutiny

FTC Chair Lina M. Khan criticized PBM practices for inflating drug costs, harming independent pharmacies, and limiting access to affordable healthcare. She called for further investigation and action against illegal practices.

PBMs Criticize the FTC Pharmacy Benefit Managers Report

The Big Three PBMs, particularly CVS Health, challenged the FTC’s conclusions, arguing the report focused on a small subset of specialty generics and ignored branded products, which make up a larger share of spending.

Need for Transparency and Regulation

The pharmacy benefit managers report stresses the financial importance of specialty generic drugs to PBMs and calls for increased transparency and regulation to ensure fair pricing in the industry.

Reference url

Recent Posts

AAP childhood obesity guidelines
     

Caution Advised: Conflicts in AAP Childhood Obesity Guidelines

Are childhood obesity guidelines driving us toward conflict? 🌍 The recent AAP guidelines suggest weight loss medications for children as young as eight, but undisclosed financial ties to drug manufacturers raise serious questions about credibility.

In this article, we dive into the implications of these conflicts and the evidence gaps surrounding pharmaceutical interventions in pediatric care. Transparency and trust are crucial when it comes to the health of our children—let’s explore what needs to change.

Read more to find out how these guidelines could impact families, clinicians, and healthcare policy.

#SyenzaNews #HealthcareInnovation #HealthcarePolicy

implantable glucose device
         

T1 Diabetes Care with an Implantable Glucose Device

🚀 Are we on the brink of a diabetes breakthrough?

A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight.

Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look!

#SyenzaNews #HealthTech #HealthEconomics #Innovation

federated learning governance
      

Federated Learning Governance in Healthcare: A Framework for Ethical and Effective Implementation

🔍 Have you considered how federated learning governance can revolutionize healthcare data collaboration?

In our latest article, we explore the critical principles of federated learning governance, emphasizing its role in managing decentralized health data while protecting patient privacy and improving research quality. Learn about the actionable strategies healthcare organizations can implement to navigate the unique challenges that come with this innovative approach.

Dive deeper into the world of federated learning in healthcare and unlock its potential for ethical and effective data use!

#SyenzaNews #AIinHealthcare #DigitalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.